RDIF and leading international co-investors close deal to invest in Doctis

Press release, 25.06.2018

Moscow, 25 June 2018 – A consortium of international investors including the Russian Direct Investment Fund (RDIF, the sovereign wealth fund of the Russian Federation), the Russia-Japan Investment Fund (RJIF, launched by RDIF, Japan Bank for International Cooperation and JBIC IG Partners) and leading funds from the Middle East, has announced the completion of a deal to invest in Doctis, a multifunctional telemedicine service company.

The investments will facilitate technological developments, improve a proprietary mobile application and create the first fully virtual clinic in Russia. It is expected that the number of doctors practising in reputable medical centres and providing consultations via the service will increase to 1,000, with up to 150,000 consultations within a year. Plans are in place to introduce artificial intelligence technology, develop a decision support system for a consulting doctor, and integrate the service with medical devices to increase the amount of objective data on the patient's health.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said:
“RDIF and partners pay special attention to investments in technology and improving quality of life. We are delighted to work with Mark Kurtser and his team on yet another project that will not only make medical care more efficient, but will also facilitate access to Russia’s most renowned and reputable doctors for residents of remote regions. Our joint objective is to create opportunities to use cutting-edge technology and equipment, ensure the Doctis project is a success and demonstrate the investment value of projects in high-tech telemedicine in Russia.”

Mark Kurtser, founder of Doctis, a professor at the Russian Academy of Sciences, said::
“It is no secret that today the lack of objective data on the patient's health is one of the obstacles for telemedicine. . That is why we see great potential in using modern medical gadgets that will help the doctor obtain the correct information for diagnosing. This technology is largely related to our Japanese investor. Doctis’ strategic goal is to provide a truly convenient tool for monitoring health and resolving any medical issues regardless of where patients live across Russia, preferably predictively or at an early stage. We are confident that with the help from our partners - RDIF and the Russia-Japan Investment Fund - we will be able to create the first fully virtual clinic in Russia.”

***

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Further information can be found at www.rdif.ru

Russia-Japan Investment Fund was established to pursue and implement attractive investment projects, which promote economic trade and investment cooperation between Japan and Russia. Priority sectors identified for cooperation include healthcare, energy, developing industries, smart cities, cutting-edge and sustainable technologies, and Russian Far Eastern District exports. It also works to support initiatives that will strengthen trade and economic relations between the two countries. Further information can be found at www.rjif.org

Doctis is a multifunctional healthcare online platform. It operates an online medical centre that allows patients to comprehensively evaluate and track their health. It partners with the state and private clinics and experts to provide services based on user's personal medical data, utilising a single online medical data storage system, which includes medical records of all family members. www.doctis.ru.

For additional information contact:
Arseniy Palagin
Russian Direct Investment Fund
Press Secretary
Tel: +7 495 644 34 14, ext. 2395
Mobile: +7 916 110 31 41
E-mail: arseniy.palagin@rdif.ru

Andrew Leach / Maria Shiryaevskaya
Hudson Sandler
Tel: +44 (0) 20 7796 4133